Assessments
peritoneal carcinomatosis, tumour, Cancer
DISEASE PROGRESSION, PERITONEAL CARCINOMATOSIS, DISEASE, TUMOUR, METASTASES, CANCER
CT examinations of the chest, abdomen, and pelvis were performed in all treatment groups at screening, on week 8, and every 12 weeks thereafter until EOT. If CT scanning was not possible, magnetic resonance imaging (MRI) was performed. For those without documented disease progression at EOT, CT scans were obtained at follow-up visits scheduled every 12 weeks. The scanning parameters were at the discretion of each hospital. All images and case report forms were sent to the central review system and anonymized. In the central review system, two board-certified abdominal radiologists (with 21 and 12 years of experience, respectively) independently reviewed the CT or MRI images on a commercial workstation equipped with a 2000 × 2000 picture archiving and communication system (Centricity 3.0, General Electric Medical Systems, Milwaukee, WI, USA) monitor with the ability to adjust the optimal window setting for each patient. At baseline, the reviewers recorded the tumour location and size in the axial plane and evaluated the tumour’s relationship with the coeliac, superior mesenteric, and common hepatic arteries and superior mesenteric and portal veins as abutment (tumour-vessel contact less than or equal to 180°) or encasement (tumour-vessel contact more than 180°). The status of resectability was determined according to the National Comprehensive Cancer Network criteria. The presence, location, and size of metastases were also recorded and specific exclusion criteria including peritoneal carcinomatosis were reviewed. They compared the baseline and follow-up CT images and determined the anatomical response (complete response, partial response, stable disease, and progression) according to RECIST 1.1. Any discrepancy between the reviewers was resolved by a consensus review, and the consensus data were used for analysis.